Previous 10 | Next 10 |
Neurocrine Biosciences (NASDAQ: NBIX ) and Voyager Therapeutics (NASDAQ: VYGR ) reports Phase I trial results for VY-AADC from eight patients with Parkinson’s disease. These Phase I results were presented at the 2019 American Academy of Neurology (AAN) Annual Meeting. More news on...
SAN DIEGO and CAMBRIDGE, Mass. , May 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced Phase I trial results for VY-AADC from eight patients with Parkinson's disease who participated in the open-label t...
SAN DIEGO , May 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the presentation of a data analysis from two Phase III studies of opicapone, a novel, once-daily, oral, selective, peripherally-acting catechol-O-methyltransferase (COMT) inhibitor for...
SAN DIEGO , April 30, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data analyses from its movement disorder programs, including INGREZZA ® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) app...
Although Neurocrine Biosciences ( NBIX ) has a strong primary commercial asset in Ingrezza, a slower-building but still promising secondary asset partnered to AbbVie ( ABBV ) in Orlissa, and an improved pipeline, the reality is that the shares of biotechs in Neurocrine’s stage of li...
Introduction It's not the best portent when AbbVie ( ABBV ) beats and raises , yet still gets a muted response as happened last week. With the 10-Q not out yet, and "risa" - now Skyrizi - on the market, that led me to read through the 10-K and read the Q1 conference call which I had lis...
Neurocrine Biosciences, Inc. (NBIX) Q1 2019 Earnings Conference Call April 29, 2019 4:30 PM ET Company Participants Kevin Gorman - Chief Executive Officer Jane Sorensen - Head, Investor Relations Matt Abernethy - Chief Financial Officer Eiry Roberts - Chief Medical Officer Er...
The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2019 Q1 earnings Read more ...
Neurocrine Biosciences (NASDAQ: NBIX ): Q1 GAAP EPS of -$1.12 misses by $0.41 . More news on: Neurocrine Biosciences, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
SAN DIEGO , April 29, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended March 31, 2019 and provided an update on the launch of INGREZZA ® (valbenazine) and its clinical development programs. ...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...